These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 21276249)

  • 1. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
    Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
    Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
    Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
    J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
    Barcus CE; O'Leary KA; Brockman JL; Rugowski DE; Liu Y; Garcia N; Yu M; Keely PJ; Eliceiri KW; Schuler LA
    Breast Cancer Res; 2017 Jan; 19(1):9. PubMed ID: 28103936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action.
    O'Leary KA; Shea MP; Salituro S; Blohm CE; Schuler LA
    Stem Cell Reports; 2017 Oct; 9(4):1167-1179. PubMed ID: 28919264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.
    Griffith OL; Chan SR; Griffith M; Krysiak K; Skidmore ZL; Hundal J; Allen JA; Arthur CD; Runci D; Bugatti M; Miceli AP; Schmidt H; Trani L; Kanchi KL; Miller CA; Larson DE; Fulton RS; Vermi W; Wilson RK; Schreiber RD; Mardis ER
    Cell Rep; 2016 Sep; 17(1):249-260. PubMed ID: 27681435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.
    Arendt LM; Grafwallner-Huseth TL; Schuler LA
    Am J Pathol; 2009 Mar; 174(3):1065-74. PubMed ID: 19179608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
    O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
    Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
    O'Leary KA; Jallow F; Rugowski DE; Sullivan R; Sinkevicius KW; Greene GL; Schuler LA
    Endocrinology; 2013 Dec; 154(12):4483-92. PubMed ID: 24064365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
    Campbell KM; O'Leary KA; Rugowski DE; Mulligan WA; Barnell EK; Skidmore ZL; Krysiak K; Griffith M; Schuler LA; Griffith OL
    Cell Rep; 2019 Aug; 28(6):1526-1537.e4. PubMed ID: 31390566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
    Zhang C; Mori M; Gao S; Li A; Hoshino I; Aupperlee MD; Haslam SZ; Xiao H
    Cancer Res; 2010 Dec; 70(24):10224-33. PubMed ID: 21159643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin drives estrogen receptor-alpha-dependent ductal expansion and synergizes with transforming growth factor-alpha to induce mammary tumors in males.
    Arendt LM; Schuler LA
    Am J Pathol; 2008 Jan; 172(1):194-202. PubMed ID: 18156207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα
    Shea MP; O'Leary KA; Fakhraldeen SA; Goffin V; Friedl A; Wisinski KB; Alexander CM; Schuler LA
    Cancer Res; 2018 Apr; 78(7):1672-1684. PubMed ID: 29363543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.
    Rose-Hellekant TA; Arendt LM; Schroeder MD; Gilchrist K; Sandgren EP; Schuler LA
    Oncogene; 2003 Jul; 22(30):4664-74. PubMed ID: 12879011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.
    Belguise K; Sonenshein GE
    J Clin Invest; 2007 Dec; 117(12):4009-21. PubMed ID: 18037997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in MNU and DMBA-induced mammary tumors in female rats.
    Alvarado A; Lopes AC; Faustino-Rocha AI; Cabrita AMS; Ferreira R; Oliveira PA; Colaço B
    Pathol Res Pract; 2017 May; 213(5):441-446. PubMed ID: 28285967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteotypic classification of spontaneous and transgenic mammary neoplasms.
    Mikaelian I; Blades N; Churchill GA; Fancher K; Knowles BB; Eppig JT; Sundberg JP
    Breast Cancer Res; 2004; 6(6):R668-79. PubMed ID: 15535849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global profiling of prolactin-modulated transcripts in breast cancer in vivo.
    Sato T; Tran TH; Peck AR; Liu C; Ertel A; Lin J; Neilson LM; Rui H
    Mol Cancer; 2013 Jun; 12():59. PubMed ID: 23758962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of ERα and FOXA1 expression in a progression model of luminal type breast cancer: insights from PyMT transgenic mouse model.
    McCune K; Mehta R; Thorat MA; Badve S; Nakshatri H
    Oncol Rep; 2010 Nov; 24(5):1233-9. PubMed ID: 20878115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.